Oncidium Foundation and Telix Pharmaceuticals Collaborate to Enhance Access to Life-Saving Cancer Therapies
Sydney, October 24th, 2023 — In a significant milestone achieved during the Belgian Economic Mission under the presidency of Her Royal Highness Princess Astrid, the Oncidium Foundation and Telix Pharmaceuticals have formalized their commitment to improving global access to innovative cancer therapies through a Memorandum of Understanding (MOU).
The Oncidium Foundation, dedicated to advancing Nuclear medicine therapies for cancer care worldwide, and Telix Pharmaceuticals, a leading global biopharmaceutical company specializing in radiopharmaceuticals, have united under the shared vision of reducing healthcare disparities, particularly in low- and middle-income countries.
The heart of this collaboration lies in the creation of the RLT-Connect Platform, an initiative that seeks to bridge the gap in access to Radioligand Therapy (RLT) Products. This platform will connect healthcare providers with Medical Radioisotope Companies, including Telix Pharmaceuticals, facilitating access to advanced cancer treatments for patients who would otherwise be without options.
“In establishing ‘RLT-Connect,’ Oncidium foundation has forged a comprehensive ecosystem—a true chain of solidarity extending from therapy centers to radiopharmacies, and Radioisotope suppliers—all united in pursuit of a common mission to ensure that every cancer patient has an equal opportunity to access a potentially life-saving technology, whoever and wherever they are.” Rebecca Lo bue, CEO of the Oncidium foundation
Telix Pharmaceuticals, as a future Radioisotope supplier, is dedicated to donating treatment doses upon the request of HCPs through the RLT-Connect Platform, providing life-saving care to those in need. Dr. Christian P. Behrenbruch, CEO of Telix Pharmaceuticals, expressed the company’s dedication to the partnership, stating, “At Telix, we are driven by the belief that every patient should have access to the best possible care. This collaboration aligns with our core mission and reaffirms our commitment to improving healthcare access globally.”
Learn more about the RLT-Connect Platform